Shares rose 5.2% post-earnings, reflecting market approval of stronger-than-expected system demand, notably robust HYDROS placements, and disciplined pricing that drove higher average selling prices.
- Total revenue reached $94.5 million, up 19% year-over-year.
- Procedure volume grew 21% to over 13,100 U.S. procedures; however, growth was softer than anticipated, driven by weaker legacy AQUABEAM account performance.
- HYDROS system placements were strong with 65 units placed, including 50 new installs and 14 replacements, underscoring successful rollout efforts.
- HYDROS average selling price increased to approximately $495,000, up from $485,000 in Q1 and $435,000 in full-year 2025.
- Strategic commercial initiatives such as salesforce realignment, replacement upgrades, and patient activation pilots are underway to support sustainable growth.
Community Discussion